Prostatype Genomics ABOSTO:PROGEN -4.23%25 PB Ratio is 0.96 as of Jul. 01, 2026, which is 4% above its 10-year median of 0.92. GuruFocus rates OSTO:PROGEN with a GF Score™ of 25/100 and a GF Value™ of kr0.11 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 195 Medical Diagnostics & Research companies, Prostatype Genomics AB ranks better than 81.54% on this metric.
The historical rank and industry rank for Prostatype Genomics AB's PB Ratio or its related term are showing as below:
OSTO:PROGEN'
s PB Ratio Range Over the Past 10 Years
Min: 0.01 Med: 0.92 Max: 19.01
Current: 0.96
During the past 7 years, Prostatype Genomics AB's highest PB Ratio was 19.01. The lowest was 0.01. And the median was 0.92.
OSTO:PROGEN's PB Ratio is ranked better than 81.54% of 195
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.02
vs OSTO:PROGEN: 0.96
During the past 12 months, Prostatype Genomics AB's average Book Value Per Share Growth Rate was -83.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -80.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -64.10% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Prostatype Genomics AB was 19.50% per year. The lowest was -80.70% per year. And the median was -42.40% per year.
Back to Basics: PB Ratio
Prostatype Genomics AB (OSTO:PROGEN) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:PROGEN vs TMO, DHR, IDXX: PB Ratio Comparison
For the Diagnostics & Research subindustry, Prostatype Genomics AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prostatype Genomics AB PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Prostatype Genomics AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Prostatype Genomics AB (OSTO:PROGEN) has a PB Ratio of 0.96 as of Jul. 01, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Prostatype Genomics AB and its competitors. This is near median its historical median of 0.92. Over the past decade, Prostatype Genomics AB's PB Ratio has ranged from 0.01 to 19.01. According to the industry distribution chart, Prostatype Genomics AB ranks #36 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 18.5%.
Is Prostatype Genomics AB's PB Ratio too high?
Prostatype Genomics AB's current PB Ratio of 0.96 is near median its 10-year median of 0.92. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 19.01. The Medical Diagnostics & Research industry median PB Ratio is 2.02. Prostatype Genomics AB's value of 0.96 is 52.5% below this industry median. Based on the distribution chart, Prostatype Genomics AB ranks #36 out of 195 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Prostatype Genomics AB has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Prostatype Genomics AB's PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Prostatype Genomics AB ranks #36 out of 195 companies for PB Ratio. This places Prostatype Genomics AB in the top 19% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.02. Prostatype Genomics AB's value of 0.96 is 52.5% below this benchmark. Historically, Prostatype Genomics AB's own PB Ratio has ranged from 0.01 to 19.01 over the past decade. While the company's 10-year median is 0.92 vs. the industry median of 2.02, Prostatype Genomics AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.02, based on 195 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prostatype Genomics AB's current PB Ratio of 0.96 is 52.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Prostatype Genomics AB and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prostatype Genomics AB's current PB Ratio is 0.96, which is near median its own 10-year median of 0.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostatype Genomics AB stock overvalued right now?
Based on GuruFocus' analysis, Prostatype Genomics AB (OSTO:PROGEN) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.11, compared to a current price of kr0.43 — trading 290.9% above its estimated fair value. The current PB Ratio is 0.96, which is near median its 10-year median of 0.92 and 52.5% below the Medical Diagnostics & Research industry median of 2.02. Prostatype Genomics AB's overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Prostatype Genomics AB (OSTO:PROGEN), the current PB Ratio is 0.96 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prostatype Genomics AB (OSTO:PROGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Prostatype Genomics AB stock appears to be overvalued.
The current stock price of kr0.43 is trading 290.9% above its estimated GF Value™ of kr0.11.
GuruFocus considers Prostatype Genomics AB to be Significantly Overvalued.
Key valuation signals for OSTO:PROGEN:
PB Ratio: 0.96 (near median its 10-year median of 0.92)
GF Value™: kr0.11 vs. price of kr0.43 (290.9% above fair value)
Industry Position: 52.5% below the Medical Diagnostics & Research median (#36 of 195)
No single metric tells the full story. See the OSTO:PROGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
25GF Score
Get the complete analysis for OSTO:PROGEN
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:PROGEN has been successfully added to your 
